Free Trial
NASDAQ:ATAI

Atai Life Sciences (ATAI) Stock Price, News & Analysis

Atai Life Sciences logo
$1.46 0.00 (0.00%)
Closing price 04/28/2025 04:00 PM Eastern
Extended Trading
$1.44 -0.02 (-1.37%)
As of 05:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Atai Life Sciences Stock (NASDAQ:ATAI)

Key Stats

Today's Range
$1.43
$1.48
50-Day Range
$1.21
$2.04
52-Week Range
$1.03
$2.57
Volume
712,901 shs
Average Volume
1.49 million shs
Market Capitalization
$291.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50
Consensus Rating
Buy

Company Overview

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Atai Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

ATAI MarketRank™: 

Atai Life Sciences scored higher than 60% of companies evaluated by MarketBeat, and ranked 432nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Atai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Atai Life Sciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Atai Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Atai Life Sciences are expected to grow in the coming year, from ($0.77) to ($0.61) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Atai Life Sciences is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Atai Life Sciences is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Atai Life Sciences has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Atai Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    8.91% of the float of Atai Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Atai Life Sciences has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Atai Life Sciences has recently increased by 3.94%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Atai Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Atai Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.91% of the float of Atai Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Atai Life Sciences has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Atai Life Sciences has recently increased by 3.94%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Atai Life Sciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Atai Life Sciences this week, compared to 2 articles on an average week.
  • Search Interest

    Only 3 people have searched for ATAI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Atai Life Sciences insiders have bought 20,428.49% more of their company's stock than they have sold. Specifically, they have bought $22,755,008.00 in company stock and sold $110,846.00 in company stock.

  • Percentage Held by Insiders

    31.20% of the stock of Atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 28.41% of the stock of Atai Life Sciences is held by institutions.

  • Read more about Atai Life Sciences' insider trading history.
Receive ATAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ATAI Stock News Headlines

Atai Life Sciences initiated with a Positive at Berenberg
Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
Psychedelic: atai Life Sciences, NRx report quarterly results
See More Headlines

ATAI Stock Analysis - Frequently Asked Questions

Atai Life Sciences' stock was trading at $1.33 at the start of the year. Since then, ATAI stock has increased by 9.8% and is now trading at $1.46.
View the best growth stocks for 2025 here
.

Atai Life Sciences (NASDAQ:ATAI) released its earnings results on Monday, March, 17th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.10. The company earned ($0.01) million during the quarter, compared to analysts' expectations of $0.30 million.

Atai Life Sciences (ATAI) raised $200 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 14,300,000 shares at $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg served as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers.

Atai Life Sciences' top institutional shareholders include Kingswood Wealth Advisors LLC (0.04%) and Regent Peak Wealth Advisors LLC (0.01%). Insiders that own company stock include Apeiron Investment Group Ltd, Life Sciences NV Atai, Florian Brand, Anne Nagengast Johnson, Sahil Kirpekar and Srinivas Rao.
View institutional ownership trends
.

Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Atai Life Sciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), CrowdStrike (CRWD) and ServiceNow (NOW).

Company Calendar

Last Earnings
3/17/2025
Today
4/28/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATAI
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.50
High Stock Price Target
$11.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+619.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-40,220,000.00
Pretax Margin
-38,531.72%

Debt

Sales & Book Value

Annual Sales
$308,000.00
Price / Cash Flow
N/A
Book Value
$1.47 per share
Price / Book
0.99

Miscellaneous

Free Float
115,448,000
Market Cap
$291.70 million
Optionable
Optionable
Beta
1.24
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:ATAI) was last updated on 4/29/2025 by MarketBeat.com Staff
From Our Partners